Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 13/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 12/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 12/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 10/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 9/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 1.00 |
| ▸ | LTA4H | P09960 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14861225 | 1.00 | HDAC6 (1.00) | HDAC6HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL1232527 | 1.00 | HDAC6 (1.00) | HDAC6HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL13039726 | 0.99 | HDAC6 (0.97) | HDAC6HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL12672623 | 0.94 | HDAC6 (0.89) | HDAC6HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL16112746 | 0.93 | HDAC6 (0.86) | HDAC6HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL17457489 | 0.93 | HDAC6 (0.86) | HDAC6HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL14883307 | 0.89 | HDAC6 (0.80) | HDAC6HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL13786320 | 0.86 | HDAC6 (0.76) | HDAC6HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL366802 | 0.86 | HDAC6 (0.76) | HDAC6HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL28215370 | 0.86 | HDAC6 (0.76) | HDAC6HDAC1HDAC2HDAC10HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705491-A2 | SMALL MOLECULE ENHANCERS FOR ADENO-ASSOCIATED VIRUS PRODUCTION | Mirus Bio LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| WO-2024229131-A9 | SMALL MOLECULE ENHANCERS FOR ADENO-ASSOCIATED VIRUS PRODUCTION | MIRUS BIO LLC (US) | 2024-12-26 | — | — | WO | claimed |
| US-20240417743-A1 | METHODS FOR IMPROVING GENOME ENGINEERING AND REGENERATION IN PLANT | KWS SAAT SE & Co. KGaA (DE) | 2024-12-19 | — | — | US | claimed |
| WO-2024229131-A2 | SMALL MOLECULE ENHANCERS FOR ADENO-ASSOCIATED VIRUS PRODUCTION | MIRUS BIO LLC (US) | 2024-11-07 | — | — | WO | claimed |
| EP-3597705-B1 | WATER ABSORBENT RESIN COMPOSITION, ABSORBENT, AND ABSORBENT ARTICLE | SUMITOMO SEIKA CHEMICALS (JP) | 2022-08-03 | — | — | EP | claimed |
| EP-3967323-A2 | HIV VACCINE | Bionor Immuno AS (NO) | 2022-03-16 | — | — | EP | claimed |
| US-20200199538-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2020-06-25 | — | — | US | claimed |
| US-20200030482-A1 | WATER ABSORBENT RESIN COMPOSITION, ABSORBENT, AND ABSORBENT ARTICLE | SUMITOMO SEIKA CHEMICALS (JP) | 2020-01-30 | — | — | US | claimed |
| CN-110582564-A | derivation of liver organoids from human pluripotent stem cells | 新加坡科技研究局 | 2019-12-17 | — | — | CN | claimed |
| WO-2011112623-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | SPECTRUM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| EP-2195029-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | Oryzon Genomics SA (ES) | 2010-06-16 | — | — | EP | claimed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | claimed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | claimed |
| WO-2009027349-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS SA (ES) | 2009-03-05 | — | — | WO | claimed |
| WO-2008090534-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF EXCESSIVE WEIGHT GAIN, REDUCTION OF INAPPROPRIATE EATING BEHAVIOURS AND INHIBITION OF BINGE EATING FOR THE TREATMENT OF OBESITY | BERAND LIMITED (IE) | 2008-07-31 | — | — | WO | claimed |
| WO-2007049262-A1 | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders | BERAND LIMITED (IE) | 2007-05-03 | — | — | WO | claimed |
| US-20060148684-A1 | Use of a histone deacetylase inhibitor for treating muscular dystrophies | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2006-07-06 | — | — | US | claimed |
| EP-1565175-A1 | USE OF A HISTONE DEACETYLASE INHIBITOR FOR TREATING MUSCULAR DYSTROPHIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-08-24 | — | — | EP | claimed |
| WO-2004050076-A1 | USE OF A HISTONE DEACETYLASE INHIBITOR FOR TREATING MUSCULAR DYSTROPHIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (FR) | 2004-06-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | HDAC6 10/4885HDAC1 1/4885HDAC2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.